Back to results
US 2025/0325531 A1Published application
Treatment of systolic dysfunction
AssigneeMyoKardia, Inc.
InventorsJean-Francois Tamby, Chun Yang, Timothy Carlson
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.
Claims30
1-53. (canceled)
A method of treating dilated cardiomyopathy (DCM) in a subject in need thereof, comprising:
- administering to the subject a first dose of danicamtiv or a pharmaceutically acceptable salt thereof for a first treatment period;
- evaluating, or having evaluated, a systolic ejection time (SET) prolongation of the subject following the first treatment period;
- selecting, or having selected, a second dose of danicamtiv or a pharmaceutically acceptable salt thereof, wherein the second dose is different than the first dose, based on the evaluation of the SET prolongation;
- administering the second dose of danicamtiv or a pharmaceutically acceptable salt thereof to the subject for a second treatment period.
1 more element
A method of treating a disease or disorder selected from systolic dysfunction, heart failure, or cardiomyopathy, in a subject in need thereof, the method comprising:
- administering to the subject a first dose of danicamtiv or a pharmaceutically acceptable salt thereof for a first treatment period;
- evaluating, or having evaluated, a systolic ejection time (SET) prolongation of the subject following the first treatment period;
- selecting, or having selected, a second dose of danicamtiv or a pharmaceutically acceptable salt thereof, wherein the second dose is different than the first dose, based on the evaluation of the SET prolongation;
- administering the second dose of danicamtiv or a pharmaceutically acceptable salt thereof to the subject for a second treatment period.
1 more element
Dependencies are inferred from the claim text.